TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

The Central Nervous System

Health Care Sector Icon

Why are you expecting big advances in the treatment of central nervous system diseases over the next few years?

The greatest biotech treatment advances of the next five or ten years are expected to occur in neuroscience, with novel treatments under development in SMA, Huntington’s, Autism, ALS, DMD, Parkinson’s and Alzheimer’s.

Recent reorganization of the FDA includes establishment of an Office of Neuroscience, driven by FDA’s focus on the great unmet need in this area, and an upcoming wave of new high-technology drug candidate reviews. Given the paucity of treatment options for diseases such as Alzheimer’s, any safe and effective therapy that makes it to market would be widely adopted.

What we’re watching:

  • Biogen’s aducanumab data
  • Roche’s gantenerumab and anti-tau trials
  • FDA regulatory flexibility
  • FDA Office of Neuroscience
Themes 2020

15 Themes to Focus on 2020: A Handbook for Portfolio Managers

Download the Handbook

People in us suffering from Alzheimer’s


Meetings of FDA’s peripheral central nervous system drugs advisory committee in 2019


Estimated US TAM for Aducanumab if approved


Alzheimer’s drugs that have failed in previous clinical trials


The US Capital building under a bright blue sky.

The Big Three For 2024- Presidential, Congress, & Policy Implications

The Gherkin sky scrapper in financial district in London.

The Current State of Liquidity in European Markets

US flags blowing in the wind.

A Tale Of Two Budgets: The New FY25 DoD Budget Is Out With Congress Still Closing The Book On FY24


New York, NY

Jun 04, 2024

8th Annual Future of the Consumer Conference

New York, NY

May 29, 2024

52nd Annual Technology, Media & Telecom Conference


Mar 19, 2024

3rd Annual Fiber-to-the-Home Symposium